Azevan
1 known investors
Azevan Pharmaceuticals develops small-molecule vasopressin V1a receptor antagonists (including SRX246, SRX251/AVN849) to treat pathological aggression and emotional dysregulation across CNS disorders such as Huntington's disease, Fragile X syndrome, intermittent explosive disorder, and mild traumatic brain injury. The company runs clinical-stage neuropsychiatric drug programs targeting underserved patient populations with no approved targeted therapies.
BiotechHealthtech